Compare ADMA Biologics Inc (ADMA) vs Entegris Inc (ENTG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Entegris Inc — how do they compare? ADMA Biologics Inc trades at $9.29 (market cap $2.13B), while Entegris Inc trades at $140.95 (market cap $20.57B). The key difference: Entegris Inc is far larger — about 9.7× ADMA Biologics Inc's market cap, and Entegris Inc pays a 0.3% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ENTG | |
|---|---|---|
Market Cap | $2.13B | $20.57B |
Sector | Health | Technology |
52-Week High | $20.38 | $184.00 |
52-Week Low | $7.60 | $68.80 |
Enterprise Value | $2.20B | $23.89B |
Dividend Yield | — | 0.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ENTG is trading at $135.08, down 7.9% today, with a bearish technical signal and neutral oscillators. The company reported strong Q1 2026 earnings of $0.86 per share, beating estimates, and maintains solid fundamentals with $3.2B revenue and 8.18% net income margin. Recent developments include a strategic cross-licensing agreement for EUV lithography and appointment of a new CFO.
Wall Street maintains a bullish outlook with 65% buy ratings and $178.40 consensus price target, representing 32% upside potential. Key risks include premium valuation (P/E 83.91), semiconductor cycle sensitivity, and execution challenges. The stock offers growth exposure to AI-driven semiconductor demand but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
